OPULUS
Welcome Guest (Log in, Subscribe
 What's New | Home | About Us | Contact Us | Help Center | Publications | Site Map | Links | Subscription 


Last update:2012.04.04.
 Regulatory Basis  Forum Issues  Intelligence Services  Web Applications  21 CFR Part 11 Compliant Products 

Search: 
CRM

Current Issues
News & Events
Forum

Products

CACTUS
LAL Proficiency Testing
LibrIN
OOS
OPULUS WEB
OpuluSafe
PyroDisk
PyroDoQ
PyroGel
PyroLab
PyroSoft
PyroSolution
PyroTrack
Twinreader
WinPyros
PyroButton

Technical Support


Adobe Acrobat Reader
Where are you now? Help Center > Products > OOS

Help Center


Still have a problem?
Technical Support

OOS

Type your keywords and find your answer fast.
Help Center This product

For more information about OOS, enter a question into the box above, or select from one of the questions below. You can select a different product from the list in the left hand panel.


Q:
Who should conduct an investigation and what departments should be included?
A: The QC unit should conduct the investigation, which should involve all other departments that could be implicated.


Q:
What kind of transient equipment malfunction can occur in LAL-endotoxin kinetic testing and how can it be resolved?

Q:
Why do I need to conduct an investigation if an OOS test result is obtained?

Q:
What is the purpose of an OOS investigation?

Q:
Who should investigate OOS?

Q:
Which parts of the CGMP regulations apply to laboratory operations?

Q:
Which section of the CGMP regulations specifies that products failing to meet established standards and other relevant quality control criteria will be rejected?

Q:
How do I handle an OOT result?

Q:
Can I ignore an OOS investigation if the rejection of a batch is based on an OOS result?

Q:
Why is it necessary to carry out an OOS investigation if the rejection of a batch is based on an OOS result?

Q:
Which sections of the CGMP regulations require that written records of the investigation are made, including conclusions of the investigation and follow-up?

Q:
How do I carry out a meaningful OOS investigation?

Q:
What should the analyst do, whenever possible, before discarding the test solution?

Q:
When do I need to conduct a complete failure investigation?

Q:
Who is responsible for the first course of action?

Q:
Who has the primary responsibility for ensuring accurate laboratory test results?

Q:
Which section of the CGMP regulations requires that the analyst should ensure that only those instruments meeting established specifications are used?

Q:
Which section of the CGMP regulations requires that the analyst should ensure that only properly calibrated instruments are used?

Q:
What is the usual time requirement during the LAL-endotoxin kinetic determination?

Q:
What should the analyst do during the testing process?

Q:
What system suitability requirements may be considered?

Q:
Why could the optical density change calculation method generate OOS results?

Q:
If signal drift is a problem, then which LAL-endotoxin kinetic curves are most likely to be affected?

Q:
What should be done in the case of obvious errors?

Q:
What should be done with OOS results if clear evidence of laboratory error exists?

Q:
What should be done if unexpected results are obtained and no obvious explanation exists?

Q:
Can you list some of the obvious errors that could invalidate results?

Q:
Is it a good idea to continue with an analysis to see what results can be obtained when an obvious error is known, and that the analysis will be invalidated at a later time for an assignable cause?

Q:
What should the supervisor's responsibilities be in the case of OOS results?

Q:
What should be included in the re-examination of an immediate assessment?

Q:
What kind of transient equipment malfunction can occur in HPLC and how can it be resolved?

Q:
How frequently is it reasonable to experience a lab error?

Q:
How should I select the procedure for an OOS failure investigation?

Q:
Who should do the retesting?

Q:
What steps should be taken during the supervisor's assessment?

Q:
What should be done with OOS results when evidence of laboratory error remains unclear?

Q:
How many times can I repeat the retests?

Q:
If varying test results are obtained, and when the evidence of laboratory error remains unclear, then what may be the cause of the OOS problem?

Q:
What practices are used in the laboratory phase of an OOS investigation?

Q:
What conditions indicate retesting?

Q:
Which section of the CGMP regulations requires the establishment of specifications, standards, sampling plans, test procedures, and other laboratory control mechanisms?

Q:
What should be done if test results obtained after the predetermined number of retests are still unsatisfactory?

Q:
If I have 2 results, one original OOS result, and one of the retest results which one should be included in the batch?

Q:
How should I document my retest results?

Q:
Can you give examples when averaging can be used?

Q:
Can you give examples when averaging cannot be used?

Q:
What conditions are required for the use of averaging?

Q:
How does resampling differ from retesting?

Q:
Based on the above problems, can I use a new sampling method?

Q:
When is resampling of the batch indicated?

Q:
Do the CGMP regulations require that the acceptance and/or rejection levels be based on statistically valid quality control criteria?

Q:
How can an outlier point generate OOS results for LAL-endotoxin testing?

Q:
What determines validity for the averaging of test data?

Q:
What corrective action can you take in case of outliers?
21 CFR Part 11 Issues
Various aspects of electronic records and electronic signatures
Forum Database
Almost 100,000 searchable messages from 16 working newsgroups. Updated regularly.
Warning Letters Knowledge Base
An extremely versatile database that will assist familiarization with the regulatory requirements
Competency Trainings & Exams
Multimedia enriched learning materials, exercises and exams.
On-line Trainings & Exams
Web-based learning materials, exercises and exams

back Back
----------------------------------
--| What's New | Home | About Us | Contact Us | Help Center | Publications | Site Map | Links | Subscription |--
© 2001-2003 OPULUS® is licensed to BioMondex Ltd. All rights reserved. Please read the disclaimer.